Asprosin-neutralizing antibodies as a treatment for metabolic syndrome.
Ila MishraClemens DuerrschmidZhiqiang KuYang HeWei XieElizabeth Sabath SilvaJennifer HoffmanWei XinNingyan ZhangYong XuZhiqiang AnAtul R ChopraPublished in: eLife (2021)
DK118290 and DK125403 (R01; National Institute of Diabetes and Digestive and Kidney Diseases), DK102529 (K08; National Institute of Diabetes and Digestive and Kidney Diseases), Caroline Wiess Law Scholarship (Baylor College of Medicine, Harrington Investigatorship Harrington Discovery Institute at University Hospitals, Cleveland); Chao Physician Scientist Award (Baylor College of Medicine); RP150551 and RP190561 (Cancer Prevention and Research Institute of Texas [CPRIT]).